iTolerance
Miami, US · Founded 2020 · Delaware corporation
iTolerance develops the SA-FasL microgel (iTOL-100) immunomodulatory technology aimed at enabling cell and tissue transplantation, such as insulin-producing islet cells for diabetes, without continuous anti-rejection drugs. The company operates in regenerative medicine and transplantation immunology.
Founders & leadership
AJ
Anthony JapourCEO
CR
Camillo RicordiChief Scientist
ES
Esma S. YolcuChief Technical Scientist
CG
Cameron GrayInterim Chief Executive Officer, Founder and Director
PA
Peter A. KienerNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$17.2M disclosed across 1 round · 2021
▶$17.2MraisedFeb 2022 · 144 investors · BiotechnologyRule 506(b)
▶$17.2MraisedFeb 2022 · 144 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Cameron GrayDirector
- Anthony JapourExecutive Officer, Director
- Peter A. KienerDirector
- Offering amount
- $20M
- Amount sold
- $17.2M
- Sales commissions
- $1.5M
- Placement agents
- National Securities Corporation
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does iTolerance do?
- iTolerance develops the SA-FasL microgel (iTOL-100) immunomodulatory technology aimed at enabling cell and tissue transplantation, such as insulin-producing islet cells for diabetes, without continuous anti-rejection drugs. The company operates in regenerative medicine and transplantation immunology.
- How much funding has iTolerance raised?
- iTolerance has disclosed $17.2M raised across 1 round.
- Where is iTolerance headquartered?
- iTolerance is headquartered in Miami, US.